Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail)

v3.21.1
Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets    
Accounts receivable $ 0 $ 234
Liabilities    
Other current liabilities 2,386 2,211
Other liabilities 1,523 1,490
Total liabilities 143,419 80,537
Takeda Pharmaceuticals Inc    
Assets    
Accounts receivable 0 234
Liabilities    
Other current liabilities 12,060 5,614
Deferred revenue, current 1,072 789
Deferred revenue, non-current 2,586 3,106
Other liabilities 0 6,711
Total liabilities $ 15,718 $ 16,220